Mithra’s new CEO has immediately signaled a potential sale for the firm’s generics business as it looks to focus on branded assets in women’s health. Meanwhile, Sawai has reorganized its management team, the longtime chair of Viatris is moving on to another role, and a former AAM vice-president has joined Sandoz.

Sandoz has confirmed dual European filings for its denosumab biosimilar rival to Prolia and Xgeva, a few months after it submitted its candidate in the US.

As Sandoz moves closer to being spun off from parent company Novartis, the generics and biosimilars firm has revealed the structure and membership of its board under chair Gilbert Ghostine.

Sandoz has made further preparations to bolster its biosimilars business ahead of its spinoff from parent company Novartis, announcing a development and manufacturing deal with Evotec at the same time as unveiling a further investment in its Holzkirchen site to transform it into a biotech development hub.